GlassScriptPhysician profile
Daniel M Dodard
NPI 1790084168
$4,956.27
in general payments reported to CMS, 2019-2025
30 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $148 · 2021: $66.32 · 2022: $428 · 2023: $1,102 · 2024: $1,127 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $695.59 | 2019-2025 | |
| Novo Nordisk INC | $505.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $494.67 | 2019-2025 | Ubrelvy, Qulipta, Skyrizi |
| Lilly USA, LLC | $449.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $444.53 | 2019-2025 | Breztri, Airsupra, Saphnelo |
| Ucb, INC. | $416.24 | 2020-2025 | Cimzia, Bimzelx |
| Amgen INC. | $326.28 | 2019-2024 | Otezla, Enbrel |
| Bayer Healthcare Pharmaceuticals INC. | $250.49 | 2023-2025 | |
| Glaxosmithkline, LLC. | $228.87 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Horizon Therapeutics Plc | $182.44 | 2019-2023 | Krystexxa |
| Dynavax Technologies Corporation | $167.84 | 2023-2025 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $108.17 | 2022-2025 | |
| Exact Sciences Corporation | $105.97 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.20 | 2019-2024 | Jardiance |
| Dexcom, INC. | $63.32 | 2024-2025 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.38 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $47.06 | 2022 | |
| Merck Sharp & Dohme LLC | $46.40 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $39.41 | 2024-2025 | Nexletol |
| Abbott Laboratories | $33.28 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $28.05 | 2019 | |
| Allergan, INC. | $27.17 | 2019 | |
| Angiodynamics, INC. | $23.58 | 2019 | |
| Fresenius Kabi USA, LLC | $22.55 | 2024 | Idacio |
| Insulet Corporation | $16.66 | 2023 | Omnipod |
| Si-Bone, INC. | $16.12 | 2024 | |
| Phadia US INC. | $15.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.74 | 2019 | |
| Medtronic, INC. | $14.06 | 2024 | Intellis Adaptivestim |
| Neuronetics, INC. | $8.32 | 2025 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.